OverviewSuggest Edit

Hikma is a multinational pharmaceutical group dedicated to improving the health and wellbeing of people in the markets it serves through the development, manufacturing and marketing of a broad range of solid, liquid and injectable generic and in-licensed pharmaceutical products.
Hikma is a leading generic pharmaceutical company with a significant presence in the Middle East and North Africa (MENA) region, the United States and Europe. It was first listed on the London Stock Exchange in 2005 is now a constituent of the FTSE 100 Index.

HQLondon, GB
Employee Ratings3.5


Hikma Pharmaceuticals is headquartered in
London, United Kingdom

Location Map

Latest Updates

Employees (est.) (Dec 2019)8,578(+2%)
Job Openings67
Revenue (FY, 2018)£1.6 B(+7%)
Share Price (Oct 2020)£26.9
Cybersecurity ratingCMore

Key People/Management at Hikma Pharmaceuticals

John Castellani

John Castellani

CREC Chair, Independent Non-Executive Director
Said Darwazah

Said Darwazah

Executive Chairman
Robert Pickering

Robert Pickering

Nomination and Governance Committee Chair, Senior Independent Director
Nina Henderson

Nina Henderson

Independent Non-Executive Director
Siggi Olafsson

Siggi Olafsson

Chief Executive Officer, Board Member
Mazen Darwazah

Mazen Darwazah

Executive Vice Chairman, President of MENA
Show more

Hikma Pharmaceuticals Office Locations

Hikma Pharmaceuticals has offices in London, Eatontown, Bouira, Rahmania and in 13 other locations
London, GB (HQ)
1 New Burlington Pl, Mayfair
Bouira, DZ
Zone D'Activite
Planegg, DE
Lochhamer Str. 13
Pavia, IT
Viale Certosa di Pavia, 10
Amman, JO
King Abdallah Ben Al Hussein Ath Thani
Al Kuwayt, KW
Ahmad Al Jaber St
Show all (20)

Hikma Pharmaceuticals Financials and Metrics

Hikma Pharmaceuticals Revenue

Embed Graph
View revenue for all periods
Hikma Pharmaceuticals's revenue was reported to be £1.64 b in FY, 2018

Revenue (FY, 2018)


Gross profit (FY, 2018)


Gross profit margin (FY, 2018), %


Net income (FY, 2018)


EBITDA (FY, 2018)


EBIT (FY, 2018)


Market capitalization (16-Oct-2020)


Closing stock price (16-Oct-2020)


Cash (31-Dec-2018)



Hikma Pharmaceuticals's current market capitalization is £6.2 b.
GBPFY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018



Revenue growth, %


Cost of goods sold


Gross profit

GBPFY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018



Accounts Receivable




Current Assets

GBPFY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income


Cash From Operating Activities


Dividends Paid


Cash From Financing Activities

GBPFY, 2004


0.2 x


0.1 x

Financial Leverage

1.7 x
Show all financial metrics

Hikma Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

Hikma Pharmaceuticals Online and Social Media Presence

Embed Graph

Hikma Pharmaceuticals News and Updates

London Markets: Hikma Pharmaceuticals soars on dividend hike but U.K. stocks falter

Hikma Pharmaceuticals led the way for the U.K.'s FTSE 100 index as the stock surged 11.3%.

Generic Oncology Drugs Market Detailed In New Research Report By Top Most Key Mylan, Aurobindo Pharma, Hikma Pharmaceuticals, Natco Pharma

The global Oncology Drugs market also give a gist on the upcoming players in the market who are ready to compete with the existing ones. This section climaxes the major statistics about the key players who are engaged in development, manufacturing, distribution, and sales, which is also included in …

Inhalation Anesthesia Market Present Scenario and the Growth Prospects 2018 – 2026 Analysis By Global Players Baxter International, Inc., Mylan NV, AbbVie, Inc., Hikma Pharmaceuticals, Piramal Healthcare etc.

Inhalation Anesthesia Market study provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players. It profiles leading players in the Global Inhalation Anesthesia Market based on the…

Hikma Pharmaceuticals Frequently Asked Questions

  • When was Hikma Pharmaceuticals founded?

    Hikma Pharmaceuticals was founded in 1978.

  • Who are Hikma Pharmaceuticals key executives?

    Hikma Pharmaceuticals's key executives are John Castellani, Said Darwazah and Robert Pickering.

  • How many employees does Hikma Pharmaceuticals have?

    Hikma Pharmaceuticals has 8,578 employees.

  • What is Hikma Pharmaceuticals revenue?

    Latest Hikma Pharmaceuticals annual revenue is £1.6 b.

  • What is Hikma Pharmaceuticals revenue per employee?

    Latest Hikma Pharmaceuticals revenue per employee is £190.6 k.

  • Who are Hikma Pharmaceuticals competitors?

    Competitors of Hikma Pharmaceuticals include Consort Medical, Jazz Pharmaceuticals and STERIS.

  • Where is Hikma Pharmaceuticals headquarters?

    Hikma Pharmaceuticals headquarters is located at 1 New Burlington Pl, Mayfair, London.

  • Where are Hikma Pharmaceuticals offices?

    Hikma Pharmaceuticals has offices in London, Eatontown, Bouira, Rahmania and in 13 other locations.

  • How many offices does Hikma Pharmaceuticals have?

    Hikma Pharmaceuticals has 20 offices.